scholarly journals Association of pigment epithelium derived factor expression with cancer progression and prognosis: a meta-analysis study

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Guo Cheng ◽  
Crystal Song
Keyword(s):  
Lymph Node ◽  
Protein Expression ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Tumor Size ◽  
Pigment Epithelium ◽  
Meta Analysis ◽  
Tnm Staging ◽  
Pathological Grade ◽  
Pigment Epithelium Derived Factor

Abstract Background Pigment epithelium derived factor (PEDF) is a secreted protein that strongly suppresses angiogenesis and directly inhibits cancer cells proliferation. The differential expression of PEDF has been observed in multiple types of human tumors. However, it is unclear as to how PEDF expression is associated with cancer progression and if PEDF could serve as a prognostic marker for cancer patients. Methods We performed a comprehensive search for the studies on PEDF expression in 14 top-ranked types of solid tumor cancer with the highest incidence. A systemic approach was used to screen for qualified studies and to extract data. Meta-analysis was performed to investigate if PEDF expression is associated with the TNM staging, tumor size, lymph node invasion, distal metastasis and pathological grade of tumor in a pan-cancer manner. A Kaplan–Meier curve was plotted with the digitally-reconstituted patient survival data to study the effect of PEDF expression on the prognosis of cancer patients. Results A total of nine studies were selected, reviewed and analyzed. Meta-analysis suggested that decreased PEDF protein expression was associated with higher TNM staging (OR = 2.13, 95% CI: 1.61–2.81), larger tumor size (OR = 1.42, 95% CI: 1.1–1.84), larger possibility of lymph node invasion (OR = 1.68, 95% CI: 1.26–2.22) and higher pathological grade (OR = 1.6, 95% CI: 1.2–2.13). No correlation was found between PEDF expression and tumor distal metastasis, gender or age. In addition, low PEDF protein level in tumor tissue is correlated with shorter overall survival (P < 0.05). Conclusions Low PEDF protein expression in cancer is significantly associated with more advanced cancer progression and significantly poorer survival. The differential clinical outcome among patients with various PEDF expression suggests its prognostic value.

scholarly journals Prognosis assessment of CD44+/CD24- in Breast Cancer Patients: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Jingjing Gu ◽  
Dandan Chen ◽  
Zhiqiang li ◽  
Yongliang Yang ◽  
Zhaoming Ma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Tumor Size ◽  
Meta Analysis ◽  
Breast Cancer Patients ◽  
Clinical Prognosis ◽  
Node Metastasis

Abstract Purpose: This meta-analysis investigated the relationships between the CD44+/CD24- phenotype and tumor size, lymph node metastasis, distant metastasis, disease-free survival (DFS), and overall survival (OS) in 8036 postoperative breast cancer patients enrolled in 23 studies.Methods: A literature search of PubMed, Medline, Cochrane, Embase, and PMC was conducted to identify eligible studies. The combined odds ratios (ORs) and 95% confidence intervals (95%CIs) were analyzed to evaluate the relationships between the CD44+/CD24- phenotype and the pathological and biological characteristics of breast cancer patients, and the combined hazard ratios (HRs) and 95% CIs were calculated to evaluate the relationships between CD44+/CD24- and DFS and OS of breast cancer petients using Stata12.0 software.Results: The CD44+/CD24- phenotype were not related to the tumor size (tumor size > 2.0 cm vs ≤ 2.0 cm, combined OR = 0.98, 95%CI: 0.68–1.34, p = 0.792) and didn’t promote lymph node metastasis (lymph node metastasis vs. no lymph node metastasis, combined OR = 0.94, 95% CI: 0.71–1.26, p = 0.692) and distant metastasis (distant metastasis vs no distant metastasis, combined OR = 3.88, 95% CI: 0.93–16.24, p = 0.064). The CD44+/CD24- phenotype was negatively correlated with postoperative DFS (HR = 1.67, 95% CI: 1.35–2.07, p <0.00001) and OS (combined HR = 1.52, 95%CI: 1.21–1.91, p = 0.0004).Conclusion: These results suggested expression of the CD44+/CD24- phenotype can be used as a reliable indicator of clinical prognosis and a potential therapeutic targets in breastcancer patients.

scholarly journals High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer

2019 ◽  
Vol 39 (6) ◽  
Author(s):  
Lin Tan ◽  
Ling Sha ◽  
Ning Hou ◽  
Mei Zhang ◽  
Qian Ma ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Distant Metastasis ◽  
Tumor Size ◽  
Prognostic Value ◽  
Pathological Grade ◽  
P53 Expression ◽  
Node Metastasis

Abstract Objectives: The present study investigated the correlation between α B-crystallin (CRYAB, HSPB5) and p53 expression in ovarian cancer and further analyzed the relationship between their expression and clinicopathology and the prognostic value of their co-expression in ovarian cancer. Methods: CRYAB and p53 expression was assessed using immunohistochemistry on ovarian cancer tumor tissues from 103 cases and validated in an independent group of 103 ovarian cancer patients. Results: High CRYAB and p53 expression rates in ovarian cancer tissues were 61.17% (63/103) and 57.28% (59/103), respectively, and their expression was positively correlated (r = 0.525, P=0.000). High CRYAB expression was significantly correlated with tumor size (P=0.028), lymph node metastasis (P=0.000), distant metastasis (P=0.005), tumor node metastasis (TNM) stage (P=0.002), and survival (P=0.000), while high p53 expression was significantly correlated with tumor size (P=0.006), pathological grade (P=0.023), lymph node metastasis (P=0.001), and survival (P=0.000). Further studies found that the high CRYAB and p53 co-expression was also significantly correlated with pathological grade (P=0.024), lymph node metastasis (P=0.000), Distant metastasis (P=0.015), TNM stage (P=0.013), and survival (P=0.000). High expression of either CRYAB or p53 and high co-expression of CRYAB and p53 were significantly correlated with poor disease-free survival (DFS) and overall survival (OS), respectively (P<0.05). Patients with high CRYAB and p53 co-expression had the worst prognoses among the groups. In addition, multivariate Cox regression models showed that high expression of either CRYAB or p53 and high co-expression of CRYAB and p53 were independent prognostic factors for DFS and OS (P<0.05). Moreover, the positive correlation and prognostic value of CRYAB and p53 expression were verified in another independent dataset. Conclusions: We demonstrated that patients with high CRYAB and p53 co-expression in ovarian cancer have significantly increased risks of recurrence, metastasis, and death compared with other patients. Therefore, more frequent follow-up of patients with high CRYAB and p53 co-expression is required. Our results also suggest that combination therapy with CRYAB inhibitors and p53 blockers may benefit future treatment of ovarian cancer patients with high co-expression of CRYAB and p53.

Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size

Cancer ◽  
2010 ◽  
Vol 116 (8) ◽  
pp. 1987-1991 ◽  
Author(s):  
Elisa Rush Port ◽  
Sujata Patil ◽  
Michelle Stempel ◽  
Monica Morrow ◽  
Hiram S. Cody
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Tumor Size ◽  
Breast Cancer Patients ◽  
Patient Age ◽  
Node Negative ◽  
Node Negative Breast Cancer

Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients

2008 ◽  
Vol 134 (11) ◽  
pp. 1229-1235 ◽  
Author(s):  
Sebastian Mayer ◽  
Axel zur Hausen ◽  
Dirk Otto Watermann ◽  
Stefan Stamm ◽  
Markus Jäger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Tumor Size ◽  
Breast Cancer Patients ◽  
Node Metastasis ◽  
Soluble Cd44

Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation

Life Sciences ◽  
2006 ◽  
Vol 79 (21) ◽  
pp. 1981-1987 ◽  
Author(s):  
Takafumi Yoshida ◽  
Sho-ichi Yamagishi ◽  
Kazuo Nakamura ◽  
Takanori Matsui ◽  
Tsutomu Imaizumi ◽  
...  
Keyword(s):  
Protein Expression ◽  
Interleukin 6 ◽  
Pigment Epithelium ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Pigment Epithelium Derived Factor ◽  
Hep3b Cells

Can primary tumor markers of cancer-initiating cells predict lymph node positivity in breast cancer patients?

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1121-1121
Author(s):  
Anees B. Chagpar ◽  
Veronique Neumeister ◽  
Donald R. Lannin ◽  
David Rimm
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Tumor Size ◽  
Primary Tumor ◽  
Poor Prognosis ◽  
Tissue Microarrays ◽  
Median Number ◽  
Breast Cancer Patients

1121 Background: Cancer initiating cells, characterized by ALDH1 positivity and/or colocalization of ALDH1 and CD44, have been shown to be associated with poor prognosis in breast cancer patients. The prognostic value of these tumor markers with respect to prediction of lymph node (LN) status remains unclear. Methods: Tissue microarrays from a cohort of 223 breast cancer patients diagnosed between 2003 and 2007 were evaluated using the AQUA method for quantitative immunofluorescence for CD44 and ALDH1. These data, along with other clinicopathologic data, were correlated with LN positivity. Results: The median patient age of the cohort was 56 (range; 26-89), with a median tumor size of 1.5 cm. 72 (32.0%) patients were LN positive. The median number of LNs excised was 3 (range; 1-27). Of the LN positive patients, the median number of positive LNs was 1.5 (range; 1-24). Levels of CD44, ALDH1, and ALDH1 colocalizing with CD44 did not correlate with number of positive LNs (Spearman rho coefficients: -0.042, 0.131, and 0.058, respectively), nor overall LN status. Tumor size and lymphovascular invasion (LVI) were the only factors found to be significantly correlated with LN status. Conclusions: While ALDH1 colocalized with CD44 has been found to be associated with poor prognosis in breast cancer patients, these markers do not predict LN status. Given that the only factors that reliably predict LN status are tumor size and LVI, further work is required to find primary tumor markers that may predict LN status in order to spare patients axillary surgery. [Table: see text]

Tumor size as a prognostic factor for colon cancer patients undergoing sentinel lymph node mapping and conventional surgery.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14046-e14046
Author(s):  
Sukamal Saha ◽  
Mohammed Nawaf Kanaan ◽  
Mohammad Mozayen ◽  
Philip Gafford ◽  
Mohammed Saifullah Shaik ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Prognostic Factor ◽  
Tumor Size ◽  
Sentinel Lymph Node Mapping ◽  
Tnm Staging ◽  
Conventional Surgery ◽  
Lymph Node Mapping ◽  
Adenocarcinoma Of The Colon

e14046 Background: Unlike other solid tumors, tumor size (TS) is not a part of the TNM staging system for colon cancer. Our goal is to correlate TS with TNM staging, nodal positivity (NP), and 5-year overall survival (OS) for patients (pts) with invasive colon cancer undergoing sentinel lymph node mapping (SLNM) vs. conventional surgery (CS). Methods: A retrospective review of 681 pts with invasive adenocarcinoma of the colon were reviewed and divided into two groups of pts (SLNM and CS). These groups were subdivided according to the size of the tumor in four groups (0-2, 2-4, 4-6 and more than 6 cm). 461 pts underwent SLNM between 1996-2010 compared to 220 pts who underwent CS between 1996-2006. The pathology reports reviewed for TS (the maximum diameter of the primary tumor), T staging, and NP. The OS was calculated from the social security database. Then all data was compared between both groups. Results: Pts with tumors <2cm were mainly T1+T2 (72%, 70%), whereas tumors >6 cm, majority of pts wereT3+T4 (94%, 85%). T1+T2 percentage consistently decreased as TS increased, and T3+T4 percentage was increasing consistently with increased TS (Table 1A). NP according to TS for SLNM pts were (16%, 53%, 56%, 48%) NP and for CS pts were (15%, 32%, 34%, 39%). In both groups, NP increased as TS increased compared to 0-2 cm group. The overall NP in both groups was 47% and 31% (Table 1B). OS for SLNM and CS pts were calculated in each group according to TS. Overall SLNM pts had better OS when compared to CS pts (65 %, 54%). Conclusions: Increasing TS was consistent with increasing T staging for both SLNM and CS pts. NP and OS were worse with increased TS for SLNM and CS pts. SLNM pts had higher NP and better outcome in OS when compared to CS pts, hence TS should be considered as a prognostic factor in pts with adenocarcinoma of the colon. [Table: see text] [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document